10-K/A: CytoSorbents Corp. Files 2025 Annual Report Amendment
Annual Report Amendment
CytoSorbents Corporation has filed an amendment to its 2025 Form 10-K, primarily to include Part III disclosures and updated executive certifications.
Summary
- This filing is an amendment (Amendment No. 1) to CytoSorbents Corporation's previously filed Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The amendment's primary purpose is to provide the information required by Part III of Form 10-K, which includes details on Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Principal Accounting Fees.
- New certifications from the Principal Executive Officer and Principal Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act, are included.
- The filing does not amend or update any financial statements or disclosures related to Items 307 and 308 of Regulation S-K.
- It should be read in conjunction with the original Form 10-K and other company filings.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is an amendment to provide required disclosures and certifications rather than new operational or financial information.
Future Outlook
This amendment does not contain new forward-looking statements or guidance beyond what was in the original 10-K filing.
Industry Context
StockSavvy.ai notes that this filing is a procedural amendment to a standard annual report, focusing on corporate governance and executive disclosures rather than operational or financial performance updates.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Independence | The Board has determined that Messrs. Bator and Sobel and Ms. Kim and Dr. Jones are independent as defined by Nasdaq listing standards. | Fiscal year ended December 31, 2025 | Ensures compliance with listing requirements and promotes objective oversight. |
| Board Leadership Structure | The Board maintains a structure with Dr. Chan as CEO and Mr. Bator as independent non-executive Chairman, deemed appropriate for balancing oversight and day-to-day management. | Fiscal year ended December 31, 2025 | Aims to provide a balance between management execution and independent board oversight. |
| Risk Oversight | The Board, primarily through the Audit Committee, oversees risk management, while management handles day-to-day processes. The Compensation Committee reviews compensation practices to avoid encouraging excessive risk-taking. | Fiscal year ended December 31, 2025 | Establishes a clear division of responsibility for risk management and aligns compensation with long-term success. |
| Audit Committee | The Audit Committee, composed of independent directors (Mr. Sobel, Mr. Bator, Dr. Jones), oversees financial reporting, internal controls, and auditor performance. Mr. Sobel is designated as an audit committee financial expert. | Fiscal year ended December 31, 2025 | Strengthens financial oversight and compliance with accounting regulations. |
| Nominating and Corporate Governance Committee | This committee (Mr. Sobel, Dr. Jones, Ms. Kim) oversees Board composition, director qualifications, Code of Conduct compliance, and related party transactions. Diversity is a key consideration for nominees. | Fiscal year ended December 31, 2025 | Ensures a qualified and diverse Board and adherence to governance best practices. |
| Compensation Committee | This committee (Mr. Bator, Ms. Kim) reviews executive compensation, ensures it does not encourage excessive risk, and administers equity plans. They deferred an analysis of Board and executive compensation for 2025. | Fiscal year ended December 31, 2025 | Oversees executive pay and incentive structures, with a deferral of a specific compensation analysis for 2025. |
| Related Person Transaction Policy | A policy is in place for reviewing and approving transactions involving related persons (directors, officers, significant shareholders) exceeding $120,000, requiring Audit Committee approval if not on arm's-length terms. | Fiscal year ended December 31, 2025 | Provides a framework for managing potential conflicts of interest and ensuring fair dealings with related parties. |
| Insider Trading Policy | Prohibits executive officers and directors from hedging or pledging Company securities. A late Form 4 filing by Mr. Michael G. Bator was noted for one transaction. | Fiscal year ended December 31, 2025 | Aims to prevent insider trading and maintain market integrity, with a minor compliance lapse noted. |
| Code of Business Conduct and Ethics | Applies to all employees and directors, with any amendments or waivers to be posted on the company website. | Fiscal year ended December 31, 2025 | Establishes ethical standards for all personnel. |
Related Party Transactions
- No related party transactions requiring disclosure under Item 404(a) of Regulation S-K occurred in 2025 or 2024, nor are any proposed.
Stakeholder Impact
- Shareholders: The filing provides transparency on corporate governance, executive compensation, and director qualifications, which are key considerations for investors.
- Employees: Executive compensation details and policies on insider trading and ethics impact employee understanding of company practices.
- Management: The filing details executive roles, compensation, and employment agreements, reinforcing their responsibilities and terms of service.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Fiscal year ended |
| 2026-03-30 | Original Form 10-K filing date |
| 2026-04-15 | Filing date of Amendment No. 1 |
Keywords
CytoSorbents Corporation, Form 10-K/A, Annual Report, SEC Filing, Corporate Governance, Executive Compensation, Sarbanes-Oxley Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.